Skip to main content
Toggle navigation
Login
Search
Home
Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Like
Tweet
Shankar Lanke, n/a
Director
Astrazeneca
Poster(s):
(M-062) Successful Dose Optimization and Recommended Phase III Dose Determination of Saruparib (PARP1 Selective Inhibitor) Through MIDD and Comprehensive Quantitative Clinical Pharmacology
Monday, November 11, 2024
7:00 AM – 5:00 PM
MST
